Department of Nephrology, The Affiliated People's Hospital, Ningbo University, Ningbo, China.
Ren Fail. 2023 Dec;45(1):2186151. doi: 10.1080/0886022X.2023.2186151.
Vascular calcification (VC) is recognized as a predictor of all-cause and CVD mortality in chronic kidney disease (CKD). VC in CKD is possibly associated with serum sclerostin. The study systematically investigated the role of serum sclerostin in VC in CKD. Following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols, a systematic search was performed of the PubMed, Cochrane Library, and EMBASE databases from inception to 11 November 2022, to identify relevant eligible studies. The data were retrieved, analyzed, and summarized. The hazard ratios (HRs) and odds ratios (ORs) with their corresponding confidence intervals (CIs) were derived and pooled. Thirteen reports (3125 patients) met the inclusion criteria and were included. Sclerostin was associated with the presence of VC (pooled OR = 2.75, 95%CI = 1.81-4.19, < 0.01) and all-cause mortality (pooled HR = 1.22, 95%CI = 1.19-1.25, < 0.01) among patients with CKD, but with a decreased risk of cardiovascular events (HR = 0.98, 95%CI = 0.97-1.00, = 0.02). This meta-analysis suggests that serum sclerostin is associated with VC and all-cause mortality among patients with CKD.
血管钙化（VC）被认为是慢性肾脏病（CKD）患者全因和心血管疾病死亡率的预测因子。CKD 中的 VC 可能与血清硬骨素有关。本研究系统地研究了血清硬骨素在 CKD 患者 VC 中的作用。按照系统评价和荟萃分析报告的首选项目，从成立到 2022 年 11 月 11 日，对 PubMed、Cochrane 图书馆和 EMBASE 数据库进行了系统检索，以确定相关的合格研究。检索、分析和总结数据。得出并汇总了风险比（HRs）和比值比（ORs）及其相应的置信区间（CIs）。符合纳入标准的有 13 份报告（3125 例患者）。硬骨素与 CKD 患者 VC 的存在（合并 OR = 2.75，95%CI = 1.81-4.19， < 0.01）和全因死亡率（合并 HR = 1.22，95%CI = 1.19-1.25， < 0.01）相关，但与心血管事件风险降低相关（HR = 0.98，95%CI = 0.97-1.00， = 0.02）。这项荟萃分析表明，血清硬骨素与 CKD 患者的 VC 和全因死亡率相关。
